Hair Growth Inhibition

Hair Growth Inhibition

Follicum’s lead drug candidate for hair growth inhibition, FOL-005, is based on a large endogenous protein that has been manipulated and modified.

Preclinical results

Independent in-vitro studies at a leading German university with FOL-005, showed effective inhibition of hair growth on living human skin tissue.

In a follow-up study on SCID mice (SCID mice are routinely used as model organisms for research on mammalian systems) which had living human skin transplanted on to them, a strong inhibition on hair growth was observed after treatment. The design of this study is as close as possible to a clinical study in humans.

As this drug candidate is based on an endogenous protein that will be broken down by the body, it is predicted that it will have no serious adverse effects on either men or women. To date no adverse reactions have been observed in the preclinical studies, the initial short term toxicological studies or in the ongoing clinical trials.


Hirsutism is a common, often distressing condition in which a woman develops excessive male pattern hair growth. It affects 5% to 10% of women of child-bearing age who often develop coarse, dark hair growth on the upper lip, chin, chest, abdomen, or back.

Hirsutism is caused by an excessive production or action of hormones called androgens, these are secreted by the ovaries or adrenal glands and also produced locally in the hair follicle. Several different conditions can lead to hirsutism, the two most common causes are polycystic ovary syndrome (PCOS) and idiopathic hirsutism.

Hirsutism requires ongoing treatment and none of today’s treatments eliminate the excessive hair growth completely. Current treatments often require constant and frequent use.